论文部分内容阅读
噻唑烷二酮(TZD)类胰岛素增敏剂是一类特定作用于胰岛素抵抗的抗糖尿病药物,通过提高脂肪和肌肉等外周组织对胰岛素的敏感性,使内源性和外源性胰岛素的作用增强,从而改善血糖控制,并延缓β细胞功能减退。马来酸罗格列酮片(商品名文迪雅)是一种强力TZD,其传统适应证为2型糖尿病,单用罗格列酮并辅以饮食控制和运动,可控制2型糖尿病的血糖;对于血糖控制不佳者,可与二甲双肌或磺酰脲类药物联用。2003年2月27日,美国食品与药品管理局(FDA)批准了罗格列酮的一项新适应证,即罗格列酮与胰岛素联用治疗2型糖尿病。罗格列酮与胰岛素联用为2型糖尿病的治疗开辟了一条崭新的途径。
Thiazolidinedione (TZD) -sensitive insulin sensitizers are a class of antidiabetic drugs that act specifically on insulin resistance by increasing the insulin sensitivity of peripheral tissues such as fat and muscle, and by the action of endogenous and exogenous insulin Enhances, improves glycemic control, and delays beta-cell dysfunction. Rosiglitazone maleate tablets (a product of Avandia) is a powerful TZD whose traditional indications are type 2 diabetes mellitus, rosiglitazone alone and supplemented with dietary control and exercise to control type 2 diabetes Blood sugar; for poor blood sugar control, with dimethyl ether or sulfonylurea drugs. On February 27, 2003, the U.S. Food and Drug Administration (FDA) approved a new indication for rosiglitazone, a combination of rosiglitazone and insulin for type 2 diabetes. The combination of rosiglitazone and insulin has opened a new avenue for the treatment of type 2 diabetes.